OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients

被引：12
作者：
Bossola, Maurizio [1 ]
Tazza, Luigi [1 ]
Luciani, Giovanna [1 ]
Tortorelli, Antonio [1 ]
Tsimikas, Sotirios [2 ]
机构：
[1] Catholic Univ, Hemodialysis Serv, Rome, Italy
[2] Univ Calif San Diego, Div Cardiovasc Dis, San Diego, CA 92103 USA
来源：
JOURNAL OF NEPHROLOGY | 2011年 / 24卷 / 05期
关键词：
Cardiovascular disease; Hemodialysis; Lipoprotein(a); Oxidized phospholipids; OxPL/apoB; LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; STAGE RENAL-DISEASE; OXIDIZED PHOSPHOLIPIDS; RISK-FACTOR; MYOCARDIAL-INFARCTION; DIALYSIS PATIENTS; OXIDATIVE STRESS; AUTOANTIBODIES; PREDICT;
D O I：
10.5301/JN.2011.6442
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Introduction: The aim of this study was to assess the correlation between oxidized phospholipids on apolipoprotein B-100 particles (OxPL/ApoB), lipoprotein(a) and low-density lipoprotein (LDL)-producing oxidized phospholipid (OxLDL) biomarkers and cardiovascular disease (CVD) in chronic hemodialysis (HD) patients. Methods: In 52 HD patients, we measured OxPL/apoB by antibody E06, IgG/IgM autoantibody titers to copper-oxidized LDL (Cu-OxLDL) and malondialdehyde (MDA)-LDL, IgG/IgM apolipoprotein B-100-immune complexes (IC/apoB), C-reactive protein (CRP) and lipoprotein(a) (Lp(a)). In all patients, the presence of CVD was assessed. Results: OxPL/ApoB, IC IgG/IgM, MDA-LDL Ig G/IgM, Cu-OxLDL IgG/IgM and Lp(a) levels were similar in patients with and without CVD. At multiple logistic regression analysis, the association between age and CVD was independent (OR=1.078; 95% confidence interval, 1.005-1.157; p=0.03). Conclusion: In HD patients, OxPL/apoB, lipoprotein(a) and OxLDL biomarkers are not associated with CVD.
引用
收藏
页码：581 / 588
页数：8
相关论文
共 37 条
[1]   Lipoprotein(a): A unique risk factor for cardiovascular disease [J].
Anuurad, Erdembileg ;
Boffa, Michael B. ;
Koschinsky, Marlys L. ;
Berglund, Lars .
CLINICS IN LABORATORY MEDICINE, 2006, 26 (04) :751-+
[2]   Lipoprotein(a) An elusive cardiovascular risk factor [J].
Berglund, L ;
Ramakrishnan, R .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (12) :2219-2226
[3]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[4]   Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: Acute effects of hemodialysis [J].
Bossola, Maurizio ;
Tazza, Luigi ;
Merki, Esther ;
Giungi, Stefania ;
Luciani, Giovanna ;
Miller, Elizabeth R. ;
Lin, Edward B. ;
Tortorelli, Antonio ;
Tsimikas, Sotirios .
BLOOD PURIFICATION, 2007, 25 (5-6) :457-465
[5]  
Brunner F P, 1992, Kidney Int Suppl, V38, pS4
[6]   Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein [J].
Cengiz, Nurcan ;
Baskin, Esra ;
Sezgin, Nurzen ;
Agras, Pinar ;
Haberal, Mehmet .
PEDIATRIC NEPHROLOGY, 2009, 24 (02) :387-393
[7]   Cardiovascular disease in end-stage renal disease patients [J].
Collins, AJ ;
Li, SL ;
Ma, JZ ;
Herzog, C .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) :S26-S29
[8]   LP(A) AND PREMATURE MORTALITY DURING CHRONIC-HEMODIALYSIS TREATMENT [J].
CRESSMAN, MD ;
ABOOD, D ;
ONEIL, J ;
HOFF, HF .
CHEMISTRY AND PHYSICS OF LIPIDS, 1994, 67-8 :419-427
[9]   Lipoprotein(a) and coronary heart disease - Meta-analysis of prospective studies [J].
Danesh, J ;
Collins, R ;
Peto, R .
CIRCULATION, 2000, 102 (10) :1082-1085
[10]   Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients [J].
Emanuele, E ;
Lusignani, LS ;
Peros, E ;
Montagna, G ;
D'Angelo, A ;
Montagna, L ;
Geroldi, D .
AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (02) :221-229
1234